CSL Could Be Barred From U.S. For Vaccine Probe Failures
This article was originally published in PharmAsia News
Executive Summary
Australia's CSL, maker of a popular influenza vaccine, is under fire by U.S. FDA and Australia's Therapeutic Goods Administration for failing to investigate problems with its major-selling drug last year